Centricity Research’s Post

It’s officially a wrap on this year’s ADA Scientific Sessions, and what a successful conference! Our team debuted a brand new booth build alongside our newly launched #whyifight campaign, made some valuable connections, and learned about some cutting edge therapies and molecules for #diabetes treatment. American Diabetes Association, we’ll see you next year in Chicago for the 85th Scientific Sessions!

🎉🎉Announcing the winner of our $500 Amazon Gift Card— Barbara Arispe of QCR Network! 🎉🎉 Barbara’s story of why she fights to advance #clinicalresearch is truly touching. She originally got into the industry after her mother passed away from Hepatitis C, an event that really inspired her to seek out change for the future of medicine. As she continued to progress through her career, she was able to work on the HAVOI Hepatitis C studies that absolutely changed the landscape of care for people with the disease. Her mother’s memory continues to inspire her to keep pushing forward. ❤️ Thank you to Barbara and the rest of our contest entrants for sharing your stories with us. We enjoyed talking to each of you! If you didn’t get a chance to see us and want to share your story, share it on LinkedIn using the hashtag #whyifight, and let’s create a movement!

Day 2 of poster presentations at American Diabetes Association 84th Scientific Sessions was a success! Dr. Kathryn Jean Lucas presented findings from the Akero Therapeutics HARMONY studies on patients with MASH and Type 2 diabetes, and Dr. Bajaj presented results from Eli Lilly and Company SURPASS studies exploring tirzepatide and Lexicon Therapeutics SOTA-INS studies on sotagliflozin. For complete poster information and study findings: ✅ Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes: https://lnkd.in/gqQhsxCH ✅ Tirzepatide as an Add-On for Participants With Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6: https://lnkd.in/eJYfk_bP ✅ Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes: https://lnkd.in/gqQhsxCH #clinicalresearch #diabetesresearch #MASH

Dr. Harpreet S. Bajaj MD, MPH, Director of Endocrine & Metabolic Research, presented illuminating data today from Novo Nordisk ONWARDS studies exploring once-weekly insulin icodec in patients with Type 2 Diabetes. For more information and complete findings: ✅ Efficacy and hypoglycemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with T2D by kidney function: ONWARDS 1–5 - https://lnkd.in/e2StfhW2 ✅ Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive T2D: post hoc analysis of ONWARDS 5 - https://lnkd.in/ech_DvaT American Diabetes Association #diabetesresearch #clinicalresearch

Tell us why you fight for the future of #diabetes care at booth 903!

The American Diabetes Association 84th Scientific Sessions Exhibit Hall is officially open and our staff would love to chat with you! Stop by booth #903 and explore our capabilities for #diabetes #clinicalresearch, learn more about our #whyifight campaign, and enter to win a $500 Amazon Gift Card!

Today we celebrate #Juneteenth - a significant day commemorating the emancipation of enslaved African Americans in the United States. It's a time to honor Black history, celebrate freedom, and reflect on the importance of #equity and #inclusion in all aspects of life, including healthcare. At Centricity Research, we are committed to fostering diversity in #clinicaltrials and ensuring #healthequity for the Black community. Join us in celebrating Juneteenth and continuing the work towards a more inclusive future. ❤️🖤💚💛

Our staff is making final preparations to head to this year's American Diabetes Association 84th Scientific Sessions June 21st through 24th in Orlando, Florida! Will we see you there? If so, stop by Booth 903 to connect with our Business Development team, meet some of our esteemed investigators, and learn more about our #clinicalresearch capabilities for #diabetes, #endocrinology, and beyond!

An oldie, but a goodie! 💡Key insights from Chief Development Officer Jeff Kingsley.